García-Martín Elena
Department of Biochemistry & Molecular Biology & Genetics, School of Biological Sciences, University of Extremadura, Avda. de Elvas s/n, E-06071, Badajoz, Spain.
Curr Drug Metab. 2008 Jul;9(6):487-97. doi: 10.2174/138920008784892155.
Genetic polymorphisms of human arylamine N-acetyltransferase 2 (NAT2) are responsible for interindividual variation in the acetylation of numerous drugs and in the transformation of aromatic and heterocyclic amines into carcinogenic intermediates. Although large interethnic variability in the frequency for NAT2 variant alleles has been reported, comparison of allele frequencies is hampered by differences in the criteria for the assignment of allelic variants. To avoid such sources of bias, in this review we analyze the occurrence of both interethnic and intraethnic variability for the seven commonest single nucleotide polymorphisms (SNP) in the NAT2 gene by using raw SNP data instead of inferred haplotypes. Besides the large interethnic variability observed for all SNPs except C282T, intraethnic variability for NAT2 SNPs was identified for the SNPs G191A among Caucasians (p<0.0001), T341C among Oriental (p<0.001) or African individuals (p<0.012), C481T among Oriental (p<0.001) or African individuals (p<0.001), and G590A among Oriental individuals (p<0.001). In contrast, no major intraethnic differences were identified for the SNPs C282T, A806G or G857A. Intraethnic variability may have relevant clinical implications. For instance, case-control NAT2 studies should not be extrapolated from one Oriental population to another. Nonsynonymous SNPs occur in 32% of alleles in Japanese individuals and in 47% of alleles in Chinese individuals, therefore the frequency of adverse effects and cancer related to slow acetylation is expected to be higher in individuals with Chinese descent than in those with Japanese descent. Intraethnic variability reinforces the need for proper selection of control subjects and points against the use of surrogate control groups for studies involving association of NAT2 alleles with adverse drug effects or spontaneous diseases.
人类芳胺N - 乙酰基转移酶2(NAT2)的基因多态性导致了众多药物乙酰化以及芳香胺和杂环胺转化为致癌中间体过程中的个体差异。尽管已报道NAT2变异等位基因频率存在较大的种族间差异,但等位基因变异分类标准的不同阻碍了等位基因频率的比较。为避免此类偏差来源,在本综述中,我们通过使用原始单核苷酸多态性(SNP)数据而非推断的单倍型,分析了NAT2基因中七个最常见单核苷酸多态性的种族间和种族内变异情况。除C282T外,所有SNP均观察到较大的种族间差异,同时还发现了NAT2 SNP在种族内的变异情况:在白种人中,G191A存在种族内变异(p<0.0001);在东方人或非洲个体中,T341C存在种族内变异(分别为p<0.001和p<0.012);在东方人或非洲个体中,C481T存在种族内变异(均为p<0.001);在东方个体中,G590A存在种族内变异(p<0.001)。相比之下,C282T、A806G或G857A这些SNP未发现主要的种族内差异。种族内变异可能具有相关的临床意义。例如,NAT2的病例对照研究不应从一个东方人群推广到另一个东方人群。非同义SNP在日本个体的等位基因中占32%,在中国个体的等位基因中占47%,因此,与慢乙酰化相关的不良反应和癌症发生频率预计在华裔个体中高于日裔个体。种族内变异进一步强调了正确选择对照受试者的必要性,并反对在涉及NAT2等位基因与药物不良反应或自发性疾病关联的研究中使用替代对照组。